December 14, 2016

AbbVie Launches Scholarship Program to Support Exceptional Students Living with Chronic Inflammatory Diseases

Share to Facebook Share to Twitter Share to Linkedin Email Sign Up for Alerts Print
- 45 higher education scholars to be awarded $15,000 each for 2017-2018 academic year
- Program is now accepting applications; submission deadline is March 31, 2017
NORTH CHICAGO, Ill., Dec. 14, 2016 – AbbVie, a global biopharmaceutical company, today announced the launch of the AbbVie Immunology Scholarship, designed to provide financial support for exceptional students living with certain chronic inflammatory diseases, as they pursue their higher education goals. For the 2017-2018 academic year, 45 scholars will be selected to receive $15,000 each. The AbbVie Immunology Scholarship is now accepting applications at
"The challenges of living with chronic inflammatory diseases can be overwhelming, and AbbVie is proud to support these dedicated students who are an inspiration as they pursue their educational ambitions,” said Tracie Haas, vice president, corporate responsibility, brand and communications, AbbVie. “As part of our continuing commitment to the community, we hope to empower more students living with inflammatory diseases to reach beyond any limitations they may experience to accomplish and excel in their goals of higher education.”
Applications for the AbbVie Immunology Scholarship will be accepted through Friday, March 31, 2017, and award recipients will be notified on Friday, April 28, 2017.


About the AbbVie Immunology Scholarship

In 2016, AbbVie provided the AbbVie Crohn's & Colitis and AbbVie Rheumatology Scholarship programs. AbbVie has expanded these programs to include inflammatory skin diseases and has renamed the program the AbbVie Immunology Scholarship.
The AbbVie Immunology Scholarship will be provided to students living with ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, or uveitis, who are seeking a trade school diploma or an associate, undergraduate or graduate degree from an accredited U.S. trade school, college or university. Recipients are chosen based on academic excellence, community involvement, written response to an essay question and ability to serve as a positive role model for the community. For more information about scholarships for the 2017-2018 academic year and to see last year’s recipients, please visit

If an applicant has been diagnosed with more than one of these inflammatory diseases, the applicant should choose the most relevant inflammatory disease for this application. Online applications will be accepted through 11:00 am ET on Friday, March 31, 2017. Completed hard-copy applications must be mailed and postmarked before the scholarship application deadline on Friday, March 31, 2017. Applications postmarked after the deadline will be ineligible.
It is not necessary for applicants to have taken, currently take or intend to take in the future any medicine or product marketed by AbbVie; this will not be a consideration in the recipient selection criteria. Employees of AbbVie and their immediate family members are not eligible. Healthcare providers and their immediate family members are not eligible. Patients contracted by AbbVie through Patient Health Perspectives are not eligible.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Media Inquiries:

Krystal Loewe